TRGA CEO comments included WST bio special. see below.
The Wall Street Transcript Publishes CEO Interviews in Biotechnology Report
NEW YORK, June 1 /PRNewswire/ -- Four leading analysts and top management from thirty-seven sector firms examine the outlook for Outlook for Biotechnology in the latest issue of The Wall Street Transcript (212/952-7433) or twst.com
In a vital review of this evolving sector for investors and industry professionals, this valuable 160-page Outlook for Outlook for Biotechnology issue features:
1) CEO interviews (average 2,500 words). Top management of thirty-seven sector firms examine the outlook for their firm and the sector. For a complete list of CEO interviews see twst.com
Looking forward, David Robinson, CEO of Ligand Pharmaceuticals (Nasdaq: LGND), states: "We are allowing R&D investments to slow their rate of growth as we make heavy investments in our commercial infrastructure to market our own products. But now that we are getting closer and closer to bringing the company to profits, we expect R&D to take off on another phase of growth in the coming years. Once again, the engine of the company long term is clearly our R&D."
Lynx Therapeutics (Nasdaq: LYNX) CEO Norman Russell declares: "Lynx's technologies are quite revolutionary: it's like re-defining the process of genomics and genetics in discovery. We will continue to grow our core genomic discovery services business by increasing our penetration of the pharmaceutical, biotechnology and agricultural markets."
Steven Katz, CEO of Ortec International (Nasdaq: ORTC), states, "In the next 12-month period, we have a lot of drivers occurring -- the approval for commercialization with the humanitarian diseases, the filing of a PMA for the burn market, and the completion of our trials for the venous and diabetic ulcers. As those things happen, we feel that the market will begin recognizing our value. So, the time to get on the train will be before those events really occur."
CEO George Usher of Polydex Pharmaceuticals Ltd. (Nasdaq: POLXF) explains: "What we have discovered over the last couple of years is that some of the veterinary pharmaceutical products and specialty chemicals that we have been manufacturing have potential human applications. So we are looking at changing, I guess, from a veterinary pharmaceutical company into more of a niche human pharmaceutical company."
Protein Polymer Technologies (OTC Bulletin Board: PPTI.OB) CEO Thomas Parmeter states: "We have looked at the possibilities of merging with another company. It's not something we haven't considered, but to date we haven't found a candidate with a fit that would make a great deal of sense. So therefore, what we've done is principally concentrate on developing strategic marketing partnerships."
Ralph Christoffersen, CEO of Ribozyme Pharmaceuticals (Nasdaq: RZYM), comments, "There are milestones in clinical trials, for example, finishing the current trials with our hepatitis ribozyme by the end of this year, and starting a pivotal trail for Angiozyme next year. Each of those represents significant steps, and typically, in biotech, those kinds of things are milestones that are rewarded in the value of the stock."
CEO Kathleen Mullinix of Synaptic Pharmaceutical (Nasdaq: SNAP) explains, "I know that our intellectual property estate will continue to grow. We presently have 91 issued patents; I think about 16 allowed and over 170 in prosecution, so that a roll-out of our asset base related to patents will continue to grow."
Michael Grey, CEO of Trega Biosciences (Nasdaq: TRGA), states, "We believe that over the next two to three years we can grow our revenues around 40% to 50% per year -- and if the product takes off, potentially more than that. But that's what we're targeting to do. And we had revenues of approximately $12 million last year, and that provides us a strong base to work from this year."
This 160-page Outlook for Biotechnology issue also features:
2) Outlook for Biotechnology - In an in-depth (9,300 words) Analyst Roundtable, Peter Drake, Managing Director, Robert Toth, Jr., Senior Analyst, and John Sonnier, Senior Biotechnology Analyst, all with Prudential Vector Healthcare Group, examine the outlook for the sector, including merger and acquisition activity, causes of volatility, new products and technology, and share specific stock recommendations.
3) Biotechnology Stocks - In an in-depth (5,800 words) Analyst Interview, Kurt von Emster, Vice President with Franklin Advisers, examines the outlook for the sector, including the extreme volatility issue in the biotechnology market, new technologies and therapeutics, and shares specific stock recommendations.
To obtain a copy of this 160-page Outlook for Biotechnology issue, call (212) 952-7433 or see twst.com
The Wall Street Transcript is a premier weekly investment publication interviewing market professionals for serious investors for over 36 years.
The Wall Street Transcript has launched a new free service where investors can ask any of the above companies (or any public company) a question at qawire.com |
